Skip to main content
OpenTrials
Completed

NCT Number: NCT01295047

Comparison of Medical Therapies in Marfan Syndrome.

The investigators are looking at the different impacts of atenolol, verapamil and perindopril on large artery and lv function in marfan syndrome. It is a double-blind, randomised cross-over trial.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The investigators recruited 21 patients with confirmed diagnosis of Marfan syndrome from two centres. The investigators performed radial artery applanation tonometry and pulse wave analysis to derive central aortic pressure and haemodynamic indexes pre-and post administering Atenolol 75mg, Perindopril 4mg and Verapamil 240mgs each for four weeks with a two week wash-out between medications. All patients underwent detailed functional and anatomical echocardiographic assessments at each visit.

Inclusion criteria

were ages 16-60 years with no treatment or β-blocker or other monotherapy only for Marfan syndrome. Patients with previous aortic dissection or aortic surgery, severe valvular regurgitation, aortic diameter at the sinotubular junction ≥ 5.0cm, contraindications to specific drug treatment, e.g. asthma and β-blocker, or those who were pregnant or at risk of pregnancy were excluded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 16-60 years old with no treatment or β-blocker or other monotherapy only for Marfan syndrome

Exclusion criteria

  • Previous aortic dissection or aortic surgery
  • Severe valvular regurgitation
  • Aortic diameter at the sinotubular junction ≥ 5.0cm
  • Contraindications to specific drug treatment, e.g. asthma and β-blocker
  • Those who were pregnant or at risk of pregnancy

Treatment and study plan

Atenolol

Drug

Verapamil

Drug

240 MG SR

perindopril

Drug

4 MG

Primary outcomes

  1. CENTRAL ARTERIAL PRESSURE

    Time frame: 18 weeks

    CENTRAL ARTERIAL PRESSURE MEASURED BY APPLANATION TONOMETRY

Secondary outcomes

  1. LARGE ARTERIAL STIFFNESS INDICES

    Time frame: 18 WEEKS

    MEASURED BY ECHO AND BY PULSE WAVE VELOCITY/ANALYSIS BY APPLANATION TONOMETRY

  2. LV Function

    Time frame: 18 WEEKS

    GLOBAL AND REGIONAL MARKERS BY ECHO

Sponsors and collaborators

Lead sponsor

Cardiff University

Other

Registry information

Official study title

Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial

Important dates

Study start
2006
Primary completion
2007
Study completion
2008
First posted
Feb 14, 2011
Registry last updated
Feb 14, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.